Presseaussendungen zu "Aplidin"

40 Aussendungen
vorige Seite Seite 3 von 3 nächste Seite

Aplidin(R) Enters Phase II Trials in Haematological Cancers

- Aplidin(R) now in Phase II trials in both solid and haematological cancers

OTE0003
25.11.2004 08:32

Aplidin(R) Granted Orphan Drug Status by the European Commission for the Treatment of Multiple Myeloma

PharmaMar announced today that Aplidin(R) (1), its second marine-derived compound in clinical development, was granted orphan drug status by the European Commission for the treatment of multiple myeloma …

OTE0004
19.11.2004 08:36

PharmaMar Reports New Data at ESMO Congress

- Significant Advances in the Clinical Development of Yondelis(TM) and Aplidin(R)

OTE0001
02.11.2004 10:52

PharmaMar's Kahalalide F, Phase II Trials for the Treatment of Severe Psoriasis

PharmaMar today announced that Kahalalide F (KF), its marine-origin compound, has entered into Phase II trials for the treatment of patients with severe psoriasis.

OTE0002
28.10.2004 08:18

Zeltia Announces Third Quarter 2004 Financial Results

The Zeltia Group (ZEL.MC) today reported financial results for the third quarter and the nine months ended September 30, 2004.

OTE0001
28.10.2004 08:15

The FDA has Granted Orphan Drug Status to Yondelis for the Treatment of STS

The United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to Yondelis in the indication of Soft Tissue Sarcoma (STS).

OTE0001
07.10.2004 08:30

FDA Grants Aplidin(R) Orphan Drug Status for the Treatment of Multiple Myeloma

PharmaMar announced today that Aplidin(R), its second marine-derived compound in Phase II clinical development, has been granted orphan drug status by the United States (US) Food and Drug Administration …

OTE0001
06.10.2004 08:43

PharmaMar Presents the First Results of its Pharmacogenomics Anticancer Drug Development Programme at the EORTC-NCI-AACR Conference

PharmaMar presented data from six studies, four of which were from pharmacogenomics research projects at the EORTC-NCI-AACR[1] International Conference on Molecular Targets and Cancer Therapeutics, held in …

OTE0001
04.10.2004 08:19

Zeltia: Bericht zum 30. Juni 2004

MADRID, Spanien, July 23 /PRNewswire/ --

OTS0090
23.07.2004 11:02

Beginn der Phase-II-Studien mit Kahalalide F an Lungenkrebs- und Melonom-Patienten

PharmaMar kündigte heute den Beginn der Phase-II-Studien mit Kahalalide F an Patienten mit nicht-kleinzelligem Lungenkarzinom (non-small cell lung cancer oder NSCLC) und mit Melanom an.

OTS0022
19.07.2004 09:23
vorige Seite nächste Seite